Shuai Wu

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (45)

• Data from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.c.6512272.v1
  +Save
• Data from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.c.6512272
  +Save
• Data from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.c.6513601.v1
  +Save
• Data from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.c.6513601
  +Save
• Figure S1 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426255.v1
  +Save
• Figure S1 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426255
  +Save
• Figure S1 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430368.v1
  +Save
• Figure S1 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430368
  +Save
• Figure S2 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426252.v1
  +Save
• Figure S2 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426252
  +Save
• Figure S2 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430365.v1
  +Save
• Figure S2 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430365
  +Save
• Figure S3 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426249.v1
  +Save
• Figure S3 from HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
  2023 DOI: 10.1158/0008-5472.22426249
  +Save
• Figure S3 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430362.v1
  +Save
• Figure S3 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430362
  +Save
• Figure S4 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430359.v1
  +Save
• Figure S4 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430359
  +Save
• Figure S5 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430356.v1
  +Save
• Figure S5 from Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers
  2023 DOI: 10.1158/0008-5472.22430356
  +Save